Literature DB >> 24969859

Endpoint of cancer treatment: targeted therapies.

Mehmet Topcul1, Idil Cetin.   

Abstract

Nowadays there are several limitations in cancer treatment. One of these is the use of conventional medicines which not only target cancer cells and thus also cause high toxicity precluding effective treatment. Recent elucidation of mechanisms that cause cancer has led to discovery of novel key molecules and pathways which have have become successful targets for the treatments that eliminate only cancer cells. These so-called targeted therapies offer new hope for millions of cancer patients, as briefly reveiwed here focusing on different types of agents, like PARP, CDK, tyrosine kinase, farnysyl transferase and proteasome inhibitors, monoclonal antibodies and antiangiogenic agents.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24969859     DOI: 10.7314/apjcp.2014.15.11.4395

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

1.  The Daniel K. Inouye College of Pharmacy Scripts: Poha Berry (Physalis peruviana) with Potential Anti-inflammatory and Cancer Prevention Activities.

Authors:  Leng Chee Chang; Mayuramas Sang-Ngern; John M Pezzuto; Carolyn Ma
Journal:  Hawaii J Med Public Health       Date:  2016-11

2.  Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers.

Authors:  Ibrahim H Eissa; Radwan El-Haggar; Mohammed A Dahab; Marwa F Ahmed; Hazem A Mahdy; Reem I Alsantali; Alaa Elwan; Nicolas Masurier; Samar S Fatahala
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights.

Authors:  Wagdy M Eldehna; Raed M Maklad; Hadia Almahli; Tarfah Al-Warhi; Eslam B Elkaeed; Mohammed A S Abourehab; Hatem A Abdel-Aziz; Ahmed M El Kerdawy
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

4.  Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.

Authors:  Tarfah Al-Warhi; Ahmed M El Kerdawy; Nada Aljaeed; Omnia E Ismael; Rezk R Ayyad; Wagdy M Eldehna; Hatem A Abdel-Aziz; Ghada H Al-Ansary
Journal:  Molecules       Date:  2020-04-27       Impact factor: 4.411

5.  Antiproliferative activity and possible mechanism of action of certain 5-methoxyindole tethered C-5 functionalized isatins.

Authors:  Maha S Almutairi; Eman S Hassan; Adam B Keeton; Gary A Piazza; Ali S Abdelhameed; Mohamed I Attia
Journal:  Drug Des Devel Ther       Date:  2019-08-27       Impact factor: 4.162

6.  Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies.

Authors:  Wagdy M Eldehna; Sara T Al-Rashood; Tarfah Al-Warhi; Razan O Eskandrani; Amal Alharbi; Ahmed M El Kerdawy
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

7.  Development of 2-oindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards colorectal cancer cells.

Authors:  Wagdy M Eldehna; Mahmoud F Abo-Ashour; Tarfah Al-Warhi; Sara T Al-Rashood; Amal Alharbi; Rezk R Ayyad; Khayal Al-Khayal; Maha Abdulla; Hatem A Abdel-Aziz; Rehan Ahmad; Radwan El-Haggar
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

8.  Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer.

Authors:  Wagdy M Eldehna; Rofaida Salem; Zainab M Elsayed; Tarfah Al-Warhi; Hamada R Knany; Rezk R Ayyad; Thamer Bin Traiki; Maha-Hamadien Abdulla; Rehan Ahmad; Hatem A Abdel-Aziz; Radwan El-Haggar
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

9.  Antiproliferative and Apoptotic Effects of Cardamonin against Hepatocellular Carcinoma HepG2 Cells.

Authors:  Nassrin A Badroon; Nazia Abdul Majid; Mohammed A Alshawsh
Journal:  Nutrients       Date:  2020-06-12       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.